Buy Carnitine chloride ampoules 100 mg/ml, 5 ml, 10 pcs
  • Buy Carnitine chloride ampoules 100 mg/ml, 5 ml, 10 pcs


Russian Heart Center
1743 Items
Dosage form
Brand & Manufacturer
Package Size
  • done All payments are SSL encrypted
  • done Full Refund if you haven't received your order
  • done International shipping to the USA, UK and Europe

Clinical Pharmacology

Carnitine chloride is an anabolic means of non-steroid nature. The drug stimulates metabolic processes, participating in various links of energy metabolism, has anabolic, antihypoxic and antithyroid action, activates lipid metabolism, stimulates regeneration, increases appetite. Carnitine is a natural substance related to vitamins of group B. It is a cofactor of metabolic processes that maintain the activity of CoA. Reduces basal metabolism, slows the breakdown of protein and carbohydrate molecules. It promotes the penetration of mitochondria through the membranes and the cleavage of long-chain fatty acids (palmitic and others) with the formation of acetyl-CoA, which is necessary to ensure the activity of pyruvate carboxylase during gluconeogenesis, the formation of ketone bodies, the synthesis of choline and its esters, oxidative phosphorylation and the formation of ATP. Mobilizes fat (the presence of three labile methyl groups) from the fat depot. Competitively displacing glucose, includes fatty acid metabolic shunt, the activity of which is not limited by oxygen (unlike aerobic glycolysis), and therefore the drug is effective in conditions of acute hypoxia (including the brain) and other critical conditions. It has a neurotrophic effect, inhibits apoptosis, limits the affected area and restores the structure of the nervous tissue. Normalizes protein and fat metabolism, increased basal metabolic rate in hyperthyroidism (being a partial thyroxin antagonist). The drug restores the alkaline reserve of blood, does not affect the blood coagulation system, reduces the formation of keto acids, increases the resistance of tissues to the effects of toxic decomposition products, activates aerobic processes and inhibits anaerobic glycolysis, has antihypoxic properties, stimulates and accelerates reparative processes.


  • Acute disorders of cerebral circulation - ischemic stroke, transient ischemic attack - in acute, subacute and recovery periods.
  • Encephalopathy.
  • Traumatic and toxic brain damage. As monotherapy or as part of complex therapy.


1 ml of solution contains: 100 mg of carnitine chloride and up to 1 ml of water for injection.

No customer reviews for the moment.

Write your review

Write your review


Dosage and Administration

The drug is administered intravenously slowly (no more than 60 drops per minute!). Before introducing the contents of one or two vials, 5-10 ml of 10% solution of carnitine chloride (0.5-1 g) - diluted in 200 ml of 0.9% sodium chloride solution for injection. In acute disorders of cerebral blood circulation, it is prescribed in the first three days 1 g once a day, and then within 7 days 0.5 g per day. After 10-12 days, repeated courses are recommended - 0.5 g once a day for 3-5 days.
When prescribing the drug in the subacute and recovery periods, with dyscirculatory encephalopathy and various brain lesions, patients are given 0.5-1 g (1-2 ampoules) of the drug once a day for 3-5 days. If necessary, after 12-14 days appoint a second course.

Adverse reactions

Allergic reactions are possible.
Muscular weakness is possible in patients with uremia.
With the rapid introduction (80 drops per minute or more), pain may occur along the veins, passing at a decrease in the rate of administration.


Hypersensitivity to carnitine chloride.

Drug interactions

When combined with carnitine chloride, glucocorticoids contribute to its accumulation in tissues (except the liver).
Other anabolic agents enhance the effect.

Pregnancy and Lactation

Special studies on the possibility of using during pregnancy and during breastfeeding have not been conducted. The decision on use should be made by evaluating the ratio of the possible risk to the child and the benefit to the mother.

Studies and clinical trials of Carnitine (Click to expand)
  1. First prenatal diagnosis of the carnitine transporter defect
  2. Quantitation of L-carnitine, acetyl-L-carnitine, propionyl-L-carnitine and their deuterated analogues by high-performance liquid chromotography tandem mass spectrometry
  3. Dietary carnitine supplements slow disease progression in a putative mouse model for hereditary ceroid-lipofuscinosis
  4. Changes in skeletal muscle histology and metabolism in patients undergoing exercise deconditioning: Effect of propionyl-L-carnitine
  5. Analysis of organic acids, amino acids, and carnitine in dogs with lipid storage myopathy
  6. Effects of a low-dose L-carnitine supplement on an adult patient with mitochondrial trifunctional protein deficiency
  7. Molecular analysis in spanish patients with muscle carnitine palmitoyltransferase deficiency
  8. Biochemical and molecular correlations in carnitine palmitoyltransferase II deficiency
  9. Cancer and anticancer therapy-induced modifications on metabolism mediated by carnitine system
  10. Two CPT2 mutations in three Japanese patients with carnitine palmitoyltransferase II deficiency: Functional analysis and association with polymorphic haplotypes and two clinical phenotypes
  11. Novel mutations associated with carnitine palmitoyltransferase II deficiency
  12. Two novel missense mutations of the OCTN2 gene (W283R and V446F) in a patient with primary systemic carnitine deficiency
  13. A missense mutation in the OCTN2 gene associated with residual carnitine transport activity
  14. Carnitine levels in patients with skeletal myopathy due to anorexia nervosa before and after refeeding
  15. Physiological mechanism-based analysis of dose-dependent gastrointestinal absorption of L-carnitine in rats
  16. Investigation of the effect of theophylline administration on total, free, short-chain acyl and long-chain acyl carnitine distributions in rat renal tissues
  17. Synthesis of [methyl-14C]crotonobetaine from DL-[methyl-14C]carnitine
  18. Nuclear magnetic resonance studies of boar seminal plasma. Problems encountered in the identification of small molecules: hypotaurine and carnitine
  19. Transport of carnitine in RBE4 cells - an in vitro model of blood-brain barrier
  20. Carnitine: An osmolyte that plays a metabolic role
  21. Identification of novel mutations in Spanish patients with muscle carnitine palmitoyltransferase II deficiency
  22. Functional analysis of mutations in the OCTN2 transporter causing primary carnitine deficiency: Lack of genotype–phenotype correlation
  23. Abnormal plasma carnitine derivatives reflecting an altered metabolic state in anorexic women at rest and following maximal effort treadmill exercise
  24. Synthesis of Poly-β-hydroxybutyrate by Agrobacterium radiobacter after Growth on D-Carnitine

8 other products in the same category: